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anti-hypertensive drug class was assessed in the calendar year (CY) 2000. The time 
to the incidence of dementia was assessed from CY2001 to CY2002. A Multivariable 
Cox regression model adjusted for sociodemographic factors, comorbidities, comedi-
cations and other factors was constructed to estimate the adjusted relative risk of 
dementia associated with use of AHT drug classes. The analysis was stratiﬁ ed for 
patients with and without hypertension. RESULTS: A total 377,838 patients were 
included in the ﬁ nal analysis. The adjusted Hazard Ratios [HRs, (95% CI)] for risk
of dementia with different classes was: Angiotensin receptor blockers (ARB) 0.76
(0.70–0.83), Angiotensin converting enzyme inhibitors (ACEI) 0.89 (0.85–0.93), CCB 
0.93 (0.89–0.97), Diuretics 0.86 (0.83–0.90), Alpha blockers 1.05(1.00–1.09) and 
Beta-Blockers 0.96 (0.92”C1.00). Only ACEI and ARB were signiﬁ cant in a stratiﬁ ed
analysis of patients with HT (ACEI 0.89, 0.85–0.93; ARB 0.78, 0.71–0.85) and 
patients without HT (ACEI 0.81, 0.69–0.94; ARB 0.55 (0.34–0.88). CONCLU-
SIONS: Drugs acting on the Renin-Angiotensin system (RAS) may be protective for 
dementia irrespective of the status of hypertension. More studies are required to
explore this association further.
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PATIENTS WITH AND WITHOUT MACROVASCULAR COMORBIDITIES
IN THE UNITED STATES
Qiu Y1, Fu AZ2, Radican L1
1Merck & Co., Inc, Whitehouse Station, NJ, USA, 2Cleveland Clinic, Cleveland, OH, USA
OBJECTIVES: Macrovascular disease remains a common and costly comorbidity
in patients with diabetes. The purpose of this study was to examine the marginal 
impact of macrovascular comorbidities on direct and indirect costs associated with 
patients with diabetes in the United States. METHODS: Using the pooled Medical
Expenditure Panel Survey (MEPS) 2003 and 2005 data, a nationally representative 
adult sample (age   18) was included in the study. Direct cost was measured by 
the total health care expenditure. Indirect cost was calculated from the lost produ-
ctivity from missed work days and additional bed days due to illness/injury based on
the 2005 average national hourly wage. The direct costs of both 2003 and 2005 data 
were adjusted to 2005 dollars. Given the heavily right-skewed distribution of the cost 
data, GLM with log-link function and gamma variance was used to identify the rela-
tionship between macrovascular conditions and costs after controlling for age, sex, 
race, ethnicity, education, income, smoking status, health insurance, and number of 
other comorbid categories. Negative binomial models were applied to analyze the 
outcomes of missed work days and bed days. All statistics were adjusted using the
proper sampling weight from the MEPS. RESULTS: The average annual health care
expense for patients with diabetes was $10,909. The average annual missed work days
and additional bed days due to illness/injury for patients with diabetes were 6.3 and 
14.8, respectively, equivalent to $2366 in total. Compared to diabetes patients without 
macrovascular comorbidities (N  3132), those with macrovascular comorbidities
(N  762) had statistically signiﬁ cant higher annual health care expenses ($3587,
p  0.001), more missed work days (4.05, p  0.01) and more bed days (7.15,
p  0.001). The marginal lost productivity cost was $1257 annually. CONCLUSIONS:
Macrovascular comorbidities in patients with diabetes result in increased direct and
indirect costs.
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OBJECTIVES: This study evaluates using Tobit regressions the costs speciﬁ c to each 
type of complication following its onset in annual increments for three years by setting 
(inpatient and outpatient). METHODS: We use a U.S. managed care database to 
identify newly diagnosed type 2 diabetics and then identify the initial onset of 
manifestations of diabetic related complications. Detailed ICD-9 codes associated 
with each type of complication were used to deﬁ ne dichotomous variables as well as 
a time to event variable, one for each selected type of complication. Outpatient and 
inpatients costs were accrued for one, two and three year periods. Because of the
number of zero costs (i.e., not everyone consumes resources such as hospitalization
annually), Tobit regressions were used, a combination of a probit probability model
and a linear regression to resolve the disproportionality in resource utilization. Param-
eter estimates from a Tobit are not directly interpretable as those from a linear regres-
sion and require transformation to obtain the predicted cost values. RESULTS: A total
of 351,900 type 2 diabetics were used in the analyses; 663 patients consumed inpatient
services compared to 226,972 patients consuming outpatient services in year one 
related to a manifestation of a diabetic related complication. For those who encoun-
tered inpatient services, ischemic heart disease ($43,269), congestive heart failure 
($43,870), ketoacidosis ($29,588) and renal manifestations ($24,995) were the most
costly. Outpatient costs for these complications were signiﬁ cantly less, $682, $781, 
$1,031, and $1,267, respectively. Following the onset of these complications addi-
tional costs continued to accrue in year 2, $50,158, $51,669, $35,080 and $28,823,
albeit at a declining rate. The total ﬁ rst year cost across all types of complications was 
$2,827 per person (a 0.00993 ﬁ rst year event rate). CONCLUSIONS: The cost of 
diabetic-related complications is considerable even in the ﬁ rst year of newly diagnosed 
type 2 patients.
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OBJECTIVES: Health technology assessment is used to inform reimbursement deci-
sions for pharmaceuticals globally. The national HTA agencies of the developed world 
have broadly similar methods and use common factors when evaluating technologies 
but sometimes come to different decisions. The aim of this study was to investigate 
the context level and product-related level factors affecting reimbursement decisions
between countries. METHODS: A systematic search was conducted to obtain the
documentation for reimbursement decisions on cancer and cardiovascular medicines. 
Where insufﬁ cient information was published, or reports were not available in English,
decisions were excluded. The analysis was conducted using multinomial logistic regres-
sions and the independent variable included three types of decision: recommended,
recommended for restricted use and not recommended. RESULTS: Detailed informa-
tion was obtained on 194 decisions from Australia, Belgium, Canada, UK, France,
and Sweden. The pooled analysis showed that 27% of medicines were recommended,
41% were recommended for restricted use and 32% were not recommended. The
results demonstrated that several factors were important in producing the different 
types of decision. These included the number of RCTs, publication date, sensitivity
analysis, budget impact, type of medicine and public interest. A sub-analysis for deci-
sions in England showed that the cost per QALY value was statistically signiﬁ cant.
CONCLUSIONS: The results may in part be explained by the different approaches
between countries to conducting economic analysis, differences in cost-effectiveness 
thresholds and variation in the weight given to economic evidence. Further variation
may be explained by factors relating to the country context such as the norms, culture
and policy objectives which inﬂ uence the methods and importance of different product 
level factors included in the HTA. The next stage of the research will investigate these 
factors directly.
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OBJECTIVES: This work describes the development of a framework for health tech-
nology decisions for Ontario Health Technology Advisory Committee (OHTAC) in
Ontario, Canada. The focus of the work is on the development of an explicit frame-
work for the recommendation of adoption of new health technologies. METHODS:
OHTAC convened a “Decision Determinants Sub-Committee” in January 2007 which 
undertook a systematic literature review and conducted key informant interviews to 
develop an explicit decision making framework. The purpose of the literature review 
and key informant interviews was to examine methods and models relevant in our 
setting. The main research questions were the following: a) what criteria are used to
make health technology recommendations?; b) what methods are used to evaluate
health technologies using these criteria (e.g., assigned weights, ranking, rating)?; and 
c) what methodology is used to synthesize these criteria (e.g., process/rules/frame-
works). RESULTS: Given the literature review and views provided by key informants,
the “Decision Determinants Sub-Committee” offered recommendations about decision
criteria, and the process by which decisions are made. Decision criteria include 1)
overall clinical beneﬁ t; 2) consistency with societal and ethical values; 3) value 
for money; and 4) feasibility of adoption into the health system. The sub-committee 
drew on several key ideas: evidence based medicine to reﬂ ect the primacy of scientiﬁ c
evidence, cost-effectiveness analysis to reﬂ ect the importance of using society’s 
resources wisely, and “Accountability for Reasonableness” to describe the elements 
of a fair decision-making process, and a deliberative process to describe how 
separate attributes of health technology ought to be evaluated and weighed. CON-
CLUSIONS: This methodology is currently being pilot tested in a live environment: 
OHTAC. It will be evaluated and revised according to its feasibility, acceptability and
perceived usefulness. The transparency of the process should enable one to have a
clear understanding of how OHTAC arrives at its recommendations regarding speciﬁ c 
technologies.
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OBJECTIVE: Advancement of innovative drugs into commercial development is
increasingly subjected to rigorous internal reviews by manufacturers for minimal 
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regulatory requirements on efﬁ cacy and safety. Target product proﬁ les (TPPs) are 
developed to evaluate critical assumptions underlying these parameters. Subsequently, 
hedonic market research tools (e.g., conjoint analysis) may be used to evaluate infor-
mally pricing/reimbursement potential based on the TPP. We explore a more direct 
approach: applying a minimal cost-effectiveness threshold used by health technology 
assessment agencies (such as the UK’s NICE) to derive formally a minimally acceptable
clinical TPP vector and a maximally acceptable value-based price. METHODS: A
generalizable, hypothetical data-based, Markov decision model was developed to 
compare experimental treatment, A, to existing standard treatment, B, in a chronic 
disease. Three sets of clinical parameters were assigned: treatment A was assumed to
offer better efﬁ cacy, a worse AE proﬁ le, and a higher risk of relapse (presumably due 
to its lesser suitability in maintenance treatment) than treatment B. Plausible quality-
adjusted life years (QALYs) and medical costs were assigned based on time in each of 
the health states of remission, progressive disease/relapse, and death. RESULTS: Using
Markov cohort analysis, at a base case TPP, one-way sensitivity analysis yielded the 
maximum justiﬁ able value-based price premium for A vs. B. For a hypothetical A vs. 
B price premium, multi-way sensitivity generated minimally acceptable TPP vectors
for A that met the reimbursement threshold. A tornado diagram analysis yielded key 
uncertainty drivers. Using Markov micro-simulation, we generated expected net mon-
etary beneﬁ t (NMB) acceptability curves for A vs. B, varying the key drivers. For TPPs
that yielded convergent NMBs across treatments, the expected value of acquiring 
additional information (VOI) with a clinical trial was generated. CONCLUSIONS:
TPPs that are explicitly derived from required cost-effectiveness thresholds should be 
used to guide drug development and to help determine price expectations.
(For HT4 see page A160) HT4
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OBJECTIVES: The objective was to examine the association between nonadherence 
to oral hypoglycemic agents and subsequent all-cause hospitalization, emergency room 
(ER) visit, and mortality among Medicare Part D enrollees with diabetes. METHODS:
This is a longitudinal retrospective cohort study. The study sample consisted of Medi-
care Part D enrollees with diabetes from six states (Alabama, California, Florida, 
Mississippi, New York, and Ohio) who had ﬁ lled at least one prescription for oral 
hypoglycemic agents during the ﬁ rst 6 months of 2006. Adherence was measured using 
proportion of days covered (PDC). Subjects were classiﬁ ed as adherent (PDC q 0.8),
poor adherent (0.5 a PDC  0.8), and very poor adherent (0  PDC  0.5). Medicare
Part A records and beneﬁ ciary ﬁ les from July 1, 2006 to March 31, 2007 were evalu-
ated for all-cause hospital admissions, ER visits, and mortality. Multivariate regression 
analyses were performed to assess the independent association between medication
adherence and outcomes. RESULTS: Data were available for 1,101,533 patients. 
Among them, 58.4% were females and the mean age was 71.7 years. About 64.9% 
were adherent, 11.2% were poor-adherent, and 24.0% were very poor-adherent
with oral hypoglycemics. After controlling for age, gender, race, and comorbidities 
(Charlson comorbidity index), in comparison to adherent patients, the odds for all-
cause hospital admission, ER visit, and mortality were 17.9% (OR: 1.179; 95%CI: 
1.156–1.204), 6.3% (OR: 1.063; 95%CI: 1.048–1.077), and 7.1% (OR: 1.071; 
95%CI: 1.037–1.106) higher for poor-adherent patients. Compared to adherent 
patients, those with very poor adherence were 22.9% (OR: 1.229; 95%CI: 1.211–
1.247), 17.1% (OR: 1.171; 95%CI: 1.160–1.183), and 10.4% (OR: 1.104; 95%CI:
1.079–1.129) more likely to be hospitalized, have visited ER, or die during outcome 
measurement period. CONCLUSIONS: The results suggest that nonadherence to oral 
hypoglycemic agents is relatively common and appears to be associated with adverse 
clinical outcomes. Medicare prescription drug plans should consider developing tar-
geted interventions to improve adherence to oral hypoglycemic agents.
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OBJECTIVES: Although racial disparities in the prevalence and associated costs of 
Alzheimer’s disease and related dementias (ADRD) have been documented in the 
elderly, no data examine whether these differences translate into differences in drug 
treatment. The objective of this study was to investigate racial disparities in the drug
therapy for ADRD and its usual manifestations, depression and psychiatric disorders.
METHODS: Community-dwelling elderly Medicare beneﬁ ciaries with ADRD were
identiﬁ ed from the 2000–2004 Medicare Current Beneﬁ ciary Survey Cost and Use ﬁ les 
linked with Medicare claims (n  2,865). Generalized estimating equations were 
employed to calculate prevalence ratios (PRs) for use of anti-dementia medications, 
anti-depressants, and anti-psychotics by race, controlling for demographic character-
istics, functional status, prescription drug insurance, and comorbidities. RESULTS:
The prevalence of ADRD was signiﬁ cantly higher in minority beneﬁ ciaries than in 
non-minority beneﬁ ciaries (8.1% vs. 5.7%, p  0.001), whereas anti-dementia medica-
tion use was 28% lower among minorities (PR  0.72, 95% conﬁ dence interval [CI]
 0.58, 0.88). Depression was common in both groups (68.4% in minorities vs. 70.8% 
in non-minorities, p  0.332), but minority beneﬁ ciaries were 40% less likely to receive 
anti-depressant therapy (PR  0.60, 95% CI  0.42, 0.85). No racial differences were
observed in prevalence of psychiatric disorders (17.6% vs. 20.8%, p  0.096) or anti-
psychotic drug use (PR  1.06, 95% CI  0.78, 1.44). CONCLUSIONS: Although 
minority Medicare beneﬁ ciaries were more likely to suffer from ADRD, they were
signiﬁ cantly less likely to receive drug therapy for the condition and the coexisting 
depression. Under-use of appropriate drug therapy may lead to expensive inpatient
hospitalization and nursing home care, resulting in poorer heath outcomes and sub-
stantial burden on the health care system. The identiﬁ cation of clinically-modiﬁ able
factors associated with under-treatment is critical to improve health outcomes and 
reduce cost.
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OBJECTIVES: To describe utilization patterns of lipid lowering drugs (LLD) and to
examine the relationship between LLD use and all-cause hospitalizations, emergency 
room visits and mortality among Medicare patients with diabetes. METHODS: This 
is a longitudinal retrospective cohort study. The study sample consisted of diabetic 
Medicare Part D beneﬁ ciaries from six states, including Alabama, California, Florida, 
Mississippi, New York and Ohio. Beneﬁ ciaries was identiﬁ ed as diabetic using a 
combination of ICD9 code for diabetes (‘250.xx’) and NDC codes for insulin or oral 
hypoglycemic agents. Utilization of LLDs in Medicare Part D records during the ﬁ rst 
6 months of 2006 was evaluated and the measure was dichotomized as not using and 
using LLD. The primary outcomes of interest were all-cause hospitalization, all-cause 
emergency room (ER) visits and all-cause mortality. Multivariable regression analysis
was performed to assess the association between LLD utilization and outcomes.
RESULTS: The study sample constituted of 1,888,682 Part D enrollees with diabetes.
Fifty-one percent of them were users of LLD. Of the users, 59% were female, 84% 
were over 65 years of age and 67% were white. In unadjusted analysis, patients who 
used LLD had lower all-cause hospitalizations (OR: 0.761, 95% CI 0.754–0.767),
lower ER visits (OR: 0.909, 95% CI 0.903–0.914) and lower all-cause mortality (OR: 
0.567 95% CI 0.559–0.574). When adjusted for age, gender, race and comorbidities
in multivariable analysis, LLD utilization remained signiﬁ cantly associated with lower 
risks for all-cause hospitalizations (OR: 0.862, 95% CI 0.854–0.869), lower ER visits 
(OR: 0.801, 95% CI 0.796–0.806) and lower all-cause mortality (OR: 0.646, 95% 
CI 0.637–0.655). CONCLUSIONS: In conclusion, approximately 50% of the patients
with diabetes received LLDs in the study period and utilization of LLDs are shown
to be associated with improved outcomes in patients with diabetes after controlling
for patient demographics and comorbidities.
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THE EFFECT OF MEDICARE PART D ON INAPPROPRIATE
PSYCHOTROPIC MEDICATION USE IN THE ELDERLY
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OBJECTIVES: The purpose of the study was to examine the impact of Medicare new
drug beneﬁ t (Part D) on the utilization of inappropriate psychotropic medications 
(IPM) in the elderly. METHODS: The effect of Part D was measured using 24 months
(2005–2006) pharmacy claims data provided by one of the largest retail pharmacy
chains in the United States. Among the approximately 70 million individuals who 
ﬁ lled prescriptions at the pharmacy chain in 2006, 11% were 65 years or older. IPM 
was deﬁ ned based on Beer’s Criteria. Segmented regression of interrupted time series 
analysis was applied to evaluate changes in the monthly prevalence of IPM that were
excluded and included in the Part D formulary in the elderly population 65 years or
older. RESULTS: Among the 2.52 million elderly who ﬁ lled psychotropic medications
in the retail pharmacy chain in 2005, 0.72 million (28.5%) ﬁ lled at least one IPM. 
The implementation of Part D caused a sudden [1.21% (P  0.0001)] and a sustained
drop [0.05% per month (P  0.037)] in the prevalence of IPM. The seniors who 
enrolled in Part D were affected more than those who did not. Of 0.74 million seniors 
who ﬁ lled IPM in 2006, only 12.81% were Part D enrollees. The reduction in IPM 
utilization was mainly due to the decrease in use of those medications excluded from 
the Part D formulary. The number of benzodiazepine and barbiturate prescriptions
(medications excluded from Part D formulary) dispensed in 2006 dropped 6.16% 
compared to 2005. There is no statistically signiﬁ cant change in the use of IPM
(antidepressants and antipsychotics) that were included in the Part D formulary. 
CONCLUSIONS: The implementation of Medicare Part D resulted in a decrease of 
IPM and thereby improving the quality of care in the elderly. Further study is war-
ranted to assess the long term effect of Part D on IPM.
